Analyse Syndax Pharmaceuticals, Inc. (SNDX) — Kairos Score 57/100

À propos de Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

Informations clés

🕴️ Activité des initiés (90 jours)

0 transactions — 0 achats et 0 ventes déclarés par les dirigeants de Syndax Pharmaceuticals, Inc..

🏦 Hedge Funds

18 fonds institutionnels déclarent une position sur SNDX dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur SNDX.

• Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
• Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.